Q linea

Q linea Enterprise Value

The Enterprise Value (EV) of Q linea (QLINEA.ST) as of Nov 3, 2026 is 196.96 M SEK. In the previous year, Enterprise Value (EV) was 574.76 M SEK — a change of -65.73% (lower).

Enterprise Value

196.96 MSEK

YoY

-65.73%

Last updated:

Enterprise Value (EV) of Q linea is 2025 196.96 M SEK. Enterprise Value (EV) of Q linea was 2024 574.76 M SEK. It decreases by -65.73% lower compared to the previous year.

The Q linea Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
-54.09 M SEK
Jan 1, 2019
243.45 M SEK
Jan 1, 2020
142.66 M SEK
Jan 1, 2021
301.43 M SEK
Jan 1, 2022
397.54 M SEK
Jan 1, 2023
387.89 M SEK
Jan 1, 2024
574.76 M SEK
Jan 1, 2025
196.96 M SEK
The Q linea Enterprise Value history
YEAREnterprise ValueYoY
196.96 MSEK-65.73%
574.76 MSEK+48.18%
387.89 MSEK-2.43%
397.54 MSEK+31.88%
301.43 MSEK+111.29%
142.66 MSEK-41.40%
243.45 MSEK-550.11%
-54.09 MSEK-112.22%
442.63 MSEK+0.15%
441.97 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q-linea AB develops and manufactures in-vitro diagnostic solutions for infectious diseases, focusing on antibiotic susceptibility testing. The company's core product, ASTar, is a fully-automated instrument that provides susceptibility profiles within three to six hours directly from positive blood cultures. This enables early targeted antibiotic administration for sepsis identification in hospital patients, primarily serving hospital laboratories. The firm measures bacteria's antimicrobial susceptibility using its own disposables, which are integral to the ASTar system's operation. Q-linea AB's revenue model is based on selling the ASTar instrument and its associated disposables to hospital laboratories. The company's product is specifically designed for sepsis identification in hospital settings, where rapid and accurate antibiotic susceptibility testing is critical. By providing a faster solution than traditional methods, Q-linea targets hospital labs seeking to improve patient outcomes in sepsis cases. The company operates as a holding company with a focus on developing and manufacturing IVD solutions. Its primary customers are hospital laboratories, which purchase the ASTar system and disposables to streamline their diagnostic processes. The firm's business model centers on the sale of both the instrument and the consumable disposables, creating recurring revenue streams from ongoing disposables usage. Q linea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q linea stock

Enterprise Value (EV) of Q linea is 196.96 M SEK in 2025.

Enterprise Value (EV) of Q linea changed from 574.76 M SEK to 196.96 M SEK, representing a -65.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Q linea since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s SEK, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' SEK varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Q linea with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Q linea

All Key Metrics — Q linea